Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome?

Area of Science:

• Cardiovascular Surgery
• Anesthesiology
• Pharmacology

Background:

• Aprotinin, a serine protease inhibitor, is used to minimize blood loss in cardiac surgery.
• This study investigates aprotinin's impact on patient outcomes, including mortality and organ dysfunction.
• Cardiac surgery patients often require blood conservation strategies.

Purpose of the Study:

• To evaluate the effect of aprotinin on postoperative outcomes in cardiac surgery patients.
• To identify independent risk factors for adverse events in patients undergoing cardiopulmonary bypass.
• To assess aprotinin's safety profile in a high-risk surgical population.

Main Methods:

• Retrospective analysis of patients on a blood conservation protocol.
• Comparison of outcomes between low-risk (no antifibrinolytic) and high-risk (aprotinin) groups.
• Logistic regression analysis to identify independent risk factors for mortality, cardiac, renal, and cerebrovascular events.

Main Results:

• Patients receiving aprotinin had higher baseline risk factors and perioperative complications.
• Aprotinin administration was not an independent predictor of mortality, cardiac events, renal failure, or cerebrovascular events.
• Independent predictors for adverse outcomes included complex surgery, preoperative heart failure, elevated creatinine, urgent/redo surgery, and advanced age.

Conclusions:

• In this high-risk cohort, aprotinin was not an independent risk factor for adverse postoperative outcomes.
• Patient selection and baseline risk factors, not aprotinin itself, were associated with complications.
• Aprotinin can be part of a blood conservation strategy for high-risk cardiac surgery patients.